News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
123 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37190)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53929)
2023 (42568)
2024 (38488)
2025 (26503)
Month
January (2488)
February (2603)
March (3228)
April (2950)
May (3962)
June (3500)
July (2854)
August (3142)
September (3205)
October (3540)
November (3386)
December (2332)
Day
1 (247)
2 (234)
3 (123)
4 (6)
5 (2)
6 (157)
7 (294)
8 (215)
9 (227)
10 (147)
11 (6)
12 (2)
13 (213)
14 (201)
15 (161)
16 (149)
17 (68)
19 (2)
20 (132)
21 (113)
22 (70)
23 (4)
24 (6)
26 (9)
27 (154)
28 (186)
29 (127)
30 (131)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
19
20
21
22
23
24
26
27
28
29
30
Business
Arbutus Announces Corporate Update and Third Quarter 2017 Financial Results
As at September 30, 2017, Arbutus had cash, cash equivalents, short-term investments and restricted investments totaling $100.8 million, as compared to $143.2 million at December 31, 2016.
November 3, 2017
·
19 min read
Business
CluePoints Builds on Late Phase Work in Japan and Launches Risk-Based Monitoring Roadshow in Tokyo
The collaborations mark the latest success for CluePoints in the region, with its centralized statistical monitoring (CSM) platform having already been used by the Nagoya University School of Medicine for an eight-year Phase III Stomach Cancer Adjuvant Multi-Institutional Group Trial (SAMIT).
November 3, 2017
·
3 min read
Deals
Celonic Acquires Glycotope’s Bio-manufacturing Facility
The acquisition is in line with Celonic’s vision to strengthen its position as a premier global player in the high-growth CDMO market, with continued investment in strategic assets and innovative technology platforms.
November 3, 2017
·
3 min read
Policy
Government Plan for New Treatments Welcomed By Alzheimer’s Research UK
The plan takes forward several recommendations from last year’s Accelerated Access Review – which examined how advances in medicine could be made available to patients faster – and could have major implications for future dementia treatments.
November 3, 2017
·
2 min read
Policy
Biosimilars Forum Applauds CMS Decision to Reverse Existing Rule on Biosimilar Reimbursement Policy
The Biosimilars Forum applauds the Centers for Medicare and Medicaid Services (CMS) decision to reverse the existing policy on biosimilar reimbursement that has been in effect since January 1, 2016.
November 3, 2017
·
1 min read
Business
Perrigo Encourages Tobacco-Free Living Through Partnership With American Cancer Society
American Cancer Society resources available through its partnership with Perrigo provide consumers with an effective roadmap to living tobacco-free.
November 3, 2017
·
2 min read
Genetown
Akebia Reports Inducement Grant to Three Newly-Hired Employees Entering Into Employment With the Company Under NASDAQ Listing Rule 5635(C)(4)
Akebia announced that the Company granted three newly-hired employees options to purchase an aggregate of 44,500 shares of Akebia’s common stock with a per share exercise price of $18.15, the closing price on the grant date.
November 3, 2017
·
1 min read
BioCapital
Aziyo Launches CanGaroo Bio Envelope for Subcutaneous Implantable Cardioverter-Defibrillators
November 3, 2017
·
3 min read
Genetown
Eleven Biotherapeutics Announces Closing of $8M Underwritten Public Offering
The company announced the closing of the previously announced underwritten public offering of 5,525,000 shares of its common stock.
November 3, 2017
·
5 min read
Drug Development
Vertex’s Phase III Studies of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis Ages 12 and Older Published in the New England Journal of Medicine
In both studies, the tezacaftor/ivacaftor combination demonstrated statistically significant and clinically meaningful improvements in lung function and other measures of disease.
November 3, 2017
·
14 min read
Previous
10 of 13
Next